EVERY medicine carries some promise. Science creates that promise, quality preserves it, and vigilance keeps it. When any one of these fails, it is not merely a manufacturing defect; it is a breach of the patient’s trust. In Pakistan, like in many developing and resource-constrained settings, healthcare systems operate under significant limitations, including supply chain complexities, infrastructure-related challenges and high patient volumes.
These realities can sometimes foster a degree of desensitisation, where minor quality concerns are overlooked amid pressing immediate needs, increasing reliance on ‘good fortune’ and the hope that ‘it will be fine’. Such attitudes are but human, and reflect resilience in the face of daily pressures, but they also carry hidden risks when it comes to medicine safety.
Families may continue using products without checking for recalls, or healthcare providers may prioritise rapid access over deeper verification in overburdened environments. This is not a criticism, but a fair observation of systemic and societal patterns seen in many societies.
Real-world evidence from international cases shows why heightened vigilance matters. In one recent case abroad, specific lots of a common over-the-counter allergy tablet meant to relieve sneezing and itching were voluntarily recalled by the manufacturer after potential cross-contamination with another substance (ranitidine) raised risks of serious hypersensitivity reactions or anaphylaxis in sensitive individuals. The incident underscored the importance of robust systems to protect patients universally.
Cross-contamination incidents have affected generics for epilepsy, diabetes, antibiotics and several other drugs, leading to recalls due to microbial issues, inadequate cleaning or supply chain problems. Health facilities have faced official scrutiny for lapses resulting in mould, bacteria or residue risks related to patient harm, hospitalisa- tions or wider outbreaks. Historical examples, such as contamination events in heparin or infant formula ingredients, demonstrate how quality gaps can escalate quickly.
Good Manufacturing Practices (GMPs) demand continuous surveillance and monitoring, real-time tracking of environmental conditions, equipment performance, pressure differentials, microbial levels and process parameters. Tools like Process Analytical Technology enable early detection of deviations, preventing variability and contamination before products reach patients. Integrating pharmaco-vigilance with manufacturing data helps catch issues promptly.
For Pakistan, the clear lesson is to build greater capacity to monitor drug dispen- sation and patient care. Waiting for a crisis to hit is not a strategy. Healthcare professionals, pharmacies and regulators need to strengthen routine checks, recall monitoring and adverse event reporting.
Besides, mass awareness must be generated to enable families and individuals to cultivate the habit of verifying medicine sources, expiry dates and to keep an eye on official alerts. Society as a whole would benefit from shifting gently from reliance on luck towards proactive awareness, a practical evolution that respects our constraints while safeguarding health outcomes.
Pharmaceutical safety is actually a shared responsibility. By embracing vigilant monitoring at every level — from global manufacturers to local dispensaries and homes — we can reduce risks and keep alive the trust that is essential to ensure effective healthcare. In a world of complex supply chains, consistent observation and care remain our strongest defence.
Roohi Bano Obaid
Karachi
Published in Dawn, October 5th, 2026
